|
1
|
Liang H, Fan JH and Qiao YL: Epidemiology,
etiology, and prevention of esophageal squamous cell carcinoma in
China. Cancer Biol Med. 14:33–41. 2017.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Deboever N, Jones CM, Yamashita K, Ajani
JA and Hofstetter WL: Advances in diagnosis and management of
cancer of the esophagus. BMJ. 385(e074962)2024.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Zeng H, Ran X, An L, Zheng R, Zhang S, Ji
JS, Zhang Y, Chen W, Wei W and He J: HBCR Working Group.
Disparities in stage at diagnosis for five common cancers in China:
A multicentre, hospital-based, observational study. Lancet Public
Health. 6:e877–e887. 2021.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Versteijne E, Van Laarhoven HW, Van Hooft
JE, van Os RM, Geijsen ED, van Berge Henegouwen MI and Hulshof MC:
Definitive chemoradiation for patients with inoperable and/or
unresectable esophageal cancer: Locoregional recurrence pattern.
Dis Esophagus. 28:453–459. 2015.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Ochi M, Murakami Y, Nishibuchi I, Kubo K,
Imano N, Takeuchi Y, Kimura T, Hamai Y, Emi M, Okada M and Nagata
Y: Long-term results of definitive chemoradiotherapy for
unresectable locally advanced esophageal squamous cell carcinoma. J
Radiat Res. 62:142–148. 2021.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Crosby T, Hurt CN, Falk S, Gollins S,
Mukherjee S, Staffurth J, Ray R, Bashir N, Bridgewater JA, Geh JI,
et al: Chemoradiotherapy with or without cetuximab in patients with
oesophageal cancer (SCOPE1): A multicentre, phase 2/3 randomised
trial. Lancet Oncol. 14:627–637. 2013.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Yang Y, Mori SV, Li M, Hinkley M, Parikh
AB, Collier KA, Miah A and Yin M: Salvage nivolumab and ipilimumab
after prior anti-PD-1/PD-L1 therapy in metastatic renal cell
carcinoma: A meta-analysis. Cancer Med. 11:1669–1677.
2022.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Jiang W, Zhang B, Xu J, Xue L and Wang L:
Current status and perspectives of esophageal cancer: A
comprehensive review. Cancer Commun (Lond): Dec 26, 2024 (Epub
ahead of print).
|
|
9
|
Cooper JS, Guo MD, Herskovic A, Macdonald
JS, Martenson JA Jr, Al-Sarraf M, Byhardt R, Russell AH, Beitler
JJ, Spencer S, et al: Chemoradiotherapy of locally advanced
esophageal cancer: long-term follow-up of a prospective randomized
trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA.
281:1623–1627. 1999.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Minsky BD, Pajak TF, Ginsberg RJ, Pisansky
TM, Martenson J, Komaki R, Okawara G, Rosenthal SA and Kelsen DP:
INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial
of combined-modality therapy for esophageal cancer: High-dose
versus standard-dose radiation therapy. J Clin Oncol. 20:1167–1174.
2002.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Leeman JE, Li JG, Pei X, Venigalla P,
Zumsteg ZS, Katsoulakis E, Lupovitch E, McBride SM, Tsai CJ, Boyle
JO, et al: Patterns of treatment failure and postrecurrence
outcomes among patients with locally advanced head and neck
squamous cell carcinoma after chemoradiotherapy using modern
radiation techniques. JAMA Oncol. 3:1487–1494. 2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Sonnick MA, Oro F, Yan B, Desai A, Wu AJ,
Shi W, Zhang Z, Gelblum DY, Paik PK, Yorke ED, et al: Identifying
the optimal radiation dose in locally advanced non-small-cell lung
cancer treated with definitive radiotherapy without concurrent
chemotherapy. Clin Lung Cancer. 19:e131–e40. 2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Jouglar E, Isnardi V, Goulon D,
Ségura-Ferlay C, Ayadi M, Dupuy C, Douillard JY, Mahé MA and Claude
L: Patterns of locoregional failure in locally advanced non-small
cell lung cancer treated with definitive conformal radiotherapy:
Results from the Gating 2006 trial. Radiother Oncol. 126:291–299.
2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Aupérin A, Le Péchoux C, Rolland E, Curran
WJ, Furuse K, Fournel P, Belderbos J, Clamon G, Ulutin HC, Paulus
R, et al: Meta-analysis of concomitant versus sequential
radiochemotherapy in locally advanced non-small-cell lung cancer. J
Clin Oncol. 28:2181–2190. 2010.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Suh YG, Lee IJ, Koom WS, Cha J, Lee JY,
Kim SK and Lee CG: High-dose versus standard-dose radiotherapy with
concurrent chemotherapy in stages II-III esophageal cancer. Jpn J
Clin Oncol. 44:534–540. 2014.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Semrau R, Herzog SL, Vallböhmer D, Kocher
M, Hölscher AH and Müller RP: Prognostic factors in definitive
radiochemotherapy of advanced inoperable esophageal cancer. Dis
Esophagus. 25:545–554. 2012.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Ren X, Wang L, Han C and Ren L:
Retrospective analysis of safety profile of high-dose concurrent
chemoradiotherapy for patients with oesophageal squamous cell
carcinoma. Radiother Oncol. 129:293–299. 2018.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Chang CL, Tsai HC, Lin WC, Chang JH, Hsu
HL, Chow JM, Yuan KS, Wu ATH and Wu SY: Dose escalation
intensity-modulated radiotherapy-based concurrent chemoradiotherapy
is effective for advanced-stage thoracic esophageal squamous cell
carcinoma. Radiother Oncol. 125:73–79. 2017.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Song T, Liang X, Fang M and Wu S:
High-dose versus conventional-dose irradiation in cisplatin-based
definitive concurrent chemoradiotherapy for esophageal cancer: A
systematic review and pooled analysis. Expert Rev Anticancer Ther.
15:1157–1169. 2015.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Hulshof MCCM, Geijsen ED, Rozema T,
Oppedijk V, Buijsen J, Neelis KJ, Nuyttens JJME, van der Sangen
MJC, Jeene PM, Reinders JG, et al: Randomized study on dose
escalation in definitive chemoradiation for patients with locally
advanced esophageal cancer (ARTDECO Study). J Clin Oncol.
39:2816–2824. 2021.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Xu Y, Dong B, Zhu W, Li J, Huang R, Sun Z,
Yang X, Liu L, He H, Liao Z, et al: A phase III multicenter
randomized clinical trial of 60 Gy versus 50 Gy Radiation dose in
concurrent chemoradiotherapy for inoperable esophageal squamous
cell carcinoma. Clin Cancer Res. 28:1792–1799. 2022.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Zhang J, Li M, Zhang K, Zheng A, Li G,
Chen S, Chen X, Li X, Sheng Y, Sun X, et al: Concurrent
Chemoradiation of Different Doses (50.4 Gy vs. 59.4 Gy) and
Different Target Field (ENI vs. IFI) for locally advanced
esophageal squamous cell carcinoma: Results from a randomized,
multicenter phase Ⅲ clinical trial. Inter J Rad Oncol Biol Phys.
114(S15)2022.
|
|
23
|
You J, Zhu S, Li J, Li J, Shen J, Zhao Y,
Li X, Jia L, Li Q, Yang J, et al: High-Dose versus standard-dose
intensity-modulated radiotherapy with concurrent paclitaxel plus
carboplatin for patients with thoracic esophageal squamous cell
carcinoma: a randomized, multicenter, open-label, phase 3
superiority Trial. Int J Radiat Oncol Biol Phys. 115:1129–1137.
2023.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Wang J, Wu Y, Zhang W, Chen Y, Liu Q, Jing
S, Zhang J, Wu F, Wang J and Qiao X: Elective nodal irradiation
versus involved-field irradiation for stage II-IV cervical
esophageal squamous cell carcinoma patients undergoing definitive
concurrent chemoradiotherapy: A retrospective propensity study with
8-year survival outcomes. Radiat Oncol. 18(142)2023.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Wang H, Song C, Zhao X, Deng W and Shen W:
The role of involved field irradiation versus elective nodal
irradiation in definitive radiotherapy or chemoradiotherapy for
esophageal cancer-a systematic review and meta-analysis. Front
Oncol. 12(1034656)2022.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Li M, Zhang X, Zhao F, Luo Y, Kong L and
Yu J: Involved-field radiotherapy for esophageal squamous cell
carcinoma: Theory and practice. Radiat Oncol. 11(18)2016.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Li Q, Zhu S, Li S and Deng W: Elective
nodal irradiation provides a superior therapeutic modality for
lymph node positivity esophageal squamous cell carcinoma patients
receiving definitive radiotherapy versus involved-field
irradiation. Medicine (Baltimore). 98(e14080)2019.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Marciscano AE, Ghasemzadeh A, Nirschl TR,
Theodros D, Kochel CM, Francica BJ, Muroyama Y, Anders RA, Sharabi
AB, Velarde E, et al: Elective nodal irradiation attenuates the
combinatorial efficacy of stereotactic radiation therapy and
immunotherapy. Clin Cancer Res. 24:5058–5071. 2018.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Dai Y, Huang D, Zhao W and Wei J: A
comparative study of elective nodal irradiation and involved field
irradiation in elderly patients with advanced esophageal cancer.
Front Oncol. 13(1323908)2023.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Shinoda M, Ando N, Kato K, Ishikura S,
Kato H, Tsubosa Y, Minashi K, Okabe H, Kimura Y, Kawano T, et al:
Randomized study of low-dose versus standard-dose chemoradiotherapy
for unresectable esophageal squamous cell carcinoma (JCOG0303).
Cancer Sci. 106:407–412. 2015.PubMed/NCBI View Article : Google Scholar
|
|
31
|
van Hagen P, Hulshof MC, van Lanschot JJ,
Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ,
Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, et al: Preoperative
chemoradiotherapy for esophageal or junctional cancer. N Engl J
Med. 366:2074–2084. 2012.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Chen Y, Ye J, Zhu Z, Zhao W, Zhou J, Wu C,
Tang H, Fan M, Li L, Lin Q, et al: Comparing paclitaxel plus
fluorouracil versus cisplatin plus fluorouracil in
chemoradiotherapy for locally advanced esophageal squamous cell
cancer: A randomized, multicenter, phase III clinical trial. J Clin
Oncol. 37:1695–1703. 2019.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Ai D, Ye J, Wei S, Li Y, Luo H, Cao J, Zhu
Z, Zhao W, Lin Q, Yang H, et al: Comparison of 3 paclitaxel-based
chemoradiotherapy regimens for patients with locally advanced
esophageal squamous cell cancer: A Randomized clinical trial. JAMA
Netw Open. 5(e220120)2022.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Owens R, Cox C, Gomberg S, Pan S,
Radhakrishna G, Parikh S, Goody R, Hingorani M, Prince S, Bird T,
et al: Outcome of weekly carboplatin-paclitaxel-based definitive
chemoradiation in oesophageal cancer in patients not considered to
be suitable for platinum-fluoropyrimidine-based treatment: a
multicentre, retrospective review. Clin Oncol (R Coll Radiol).
32:121–130. 2020.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Yada M, Yamamoto S, Honma Y, Hirano H,
Okita N, Shoji H, Iwasa S, Takashima A, Nagahara A and Kato K:
Retrospective analysis of definitive chemoradiotherapy with FOLFOX
in patients with esophageal cancer intolerant to cisplatin. In
Vivo. 38:761–766. 2024.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Satake H, Tahara M, Mochizuki S, Kato K,
Hara H, Yokota T, Kiyota N, Kii T, Chin K, Zenda S, et al: A
prospective, multicenter phase I/II study of induction chemotherapy
with docetaxel, cisplatin and fluorouracil (DCF) followed by
chemoradiotherapy in patients with unresectable locally advanced
esophageal carcinoma. Cancer Chemother Pharmacol. 78:91–99.
2016.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Sakai M, Sohda M, Saito H, Nakazawa N,
Ubukata Y, Kuriyama K, Hara K, Sano A, Ogawa H, Yokobori T, et al:
Concurrent chemoradiotherapy with docetaxel, cisplatin, and
5-fluorouracil (DCF-RT) vs. cisplatin and 5-fluorouracil (CF-RT)
for patients with unresectable locally advanced esophageal cancer
in a real-world clinical setting. Anticancer Res. 41:2141–2145.
2014.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Kurtulus S, Madi A, Escobar G, Klapholz M,
Nyman J, Christian E, Pawlak M, Dionne D, Xia J, Rozenblatt-Rosen
O, et al: Checkpoint blockade immunotherapy induces dynamic changes
in PD-1(-)CD8(+) tumor-infiltrating T cells. Immunity.
50:181–194.e6. 2019.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Yang YM, Hong P, Xu WW, He QY and Li B:
Advances in targeted therapy for esophageal cancer. Signal
Transduct Target Ther. 5(229)2020.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Ko EC, Raben D and Formenti SC: The
integration of radiotherapy with immunotherapy for the treatment of
non-small cell lung cancer. Clin Cancer Res. 24:5792–5806.
2018.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Filatenkov A, Baker J, Mueller AM, Kenkel
J, Ahn GO, Dutt S, Zhang N, Kohrt H, Jensen K, Dejbakhsh-Jones S,
et al: Ablative tumor radiation can change the tumor immune cell
microenvironment to induce durable complete remissions. Clin Cancer
Res. 21:3727–3739. 2015.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Demaria S, Guha C, Schoenfeld J, Morris Z,
Monjazeb A, Sikora A, Crittenden M, Shiao S, Khleif S, Gupta S, et
al: Radiation dose and fraction in immunotherapy: One-size regimen
does not fit all settings, so how does one choose? J Immunother
Cancer. 9(e002038)2021.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Salas-Benito D, Pérez-Gracia Jl,
Ponz-Sarvisé M, Rodriguez-Ruiz ME, Martínez-Forero I, Castañón E,
López-Picazo JM, Sanmamed MF and Melero I: Paradigms on
immunotherapy combinations with chemotherapy. Cancer Discov.
11:1353–1367. 2021.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Lian HM, Wu JL, Liufu WJ, Yu TT, Niu SQ,
Bao Y and Peng F: Induction immunotherapy plus chemotherapy
followed by definitive chemoradiation therapy in locally advanced
esophageal squamous cell carcinoma: A propensity-score matched
study. Cancer Immunol Immunother. 73(55)2024.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Wang J, Cheng Y, Wu Y, Cao F, Liu Q and
Gao G: 978P A prospective study of camrelizumab monotherapy
following definitive concurrent chemoradiotherapy in patients with
unresectable locally advanced esophageal squamous cell cancer. Ann
Oncol. 32(S838)2021.
|
|
46
|
Zhang W, Yan C, Zhang T, Chen X, Dong J,
Zhao J, Han D, Wang J, Zhao G and Cao F: , et al: Addition
of camrelizumab to docetaxel, cisplatin, and radiation therapy in
patients with locally advanced esophageal squamous cell carcinoma:
A phase 1b study. Oncoimmunology. 10(1971418)2021.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Park S, Oh D, Choi YL, Chi SA, Kim K, Ahn
MJ and Sun JM: Durvalumab and tremelimumab with definitive
chemoradiotherapy for locally advanced esophageal squamous cell
carcinoma. Cancer. 128:2148–2158. 2022.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Zhu Y, Wen J, Li Q, Chen B, Zhao L, Liu S,
Yang Y, Wang S, Lv Y, Li J, et al: Toripalimab combined with
definitive chemoradiotherapy in locally advanced oesophageal
squamous cell carcinoma (EC-CRT-001): A single-arm, phase 2 trial.
Lancet Oncol. 24:371–382. 2023.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Wang R, Ling Y, Chen B, Zhu Y, Hu Y, Liu
M, Yang Y, Zhang L, Lv Y, Liu S, et al: Long-term survival and
post-hoc analysis of toripalimab plus definitive chemoradiotherapy
for oesophageal squamous cell carcinoma: Insights from the
EC-CRT-001 phase II trial. EClinicalMedicine,. 2024, 75: 102806,
2024.
|
|
50
|
Conroy T, Galais MP, Raoul JL, Bouché O,
Gourgou-Bourgade S, Douillard JY, Etienne PL, Boige V, Martel-Lafay
I, Michel P, et al: Definitive chemoradiotherapy with FOLFOX versus
fluorouracil and cisplatin in patients with oesophageal cancer
(PRODIGE5/ACCORD17): Final results of a randomised, phase 2/3
trial. Lancet Oncol. 15:305–314. 2014.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Gao LR, Wang X, Han W, Deng W, Li C, Wang
X, Zhao Y, Ni W, Chang X, Zhou Z, et al: A multicenter prospective
phase III clinical randomized study of simultaneous integrated
boost intensity-modulated radiotherapy with or without concurrent
chemotherapy in patients with esophageal cancer: 3JECROG P-02 study
protocol. BMC Cancer. 20(901)2020.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Ristau J, Thiel M, Katayama S, Schlampp I,
Lang K, Häfner MF, Herfarth K, Debus J and Koerber SA: Simultaneous
integrated boost concepts in definitive radiation therapy for
esophageal cancer: Outcomes and toxicity. Radiat Oncol.
16(23)2021.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Eze C, Schmidt-Hegemann NS, Sawicki LM,
Walter F and Manapov F: Revisiting the role of dose escalation in
esophageal cancer in the era of modern radiation delivery. J Thorac
Dis. 12:1624–1627. 2020.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Chang CL, Lin KC, Chen WM, Shia BC and Wu
SY: Comparative effectiveness of intensity-modulated proton therapy
versus intensity-modulated radiotherapy for patients with
inoperable esophageal squamous cell carcinoma undergoing
curative-intent concurrent chemoradiotherapy. J Thorac Oncol.
19:818–828. 2024.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Pöttgen C, Gkika E, Stahl M, Abu Jawad J,
Gauler T, Kasper S, Trarbach T, Herrmann K, Lehmann N, Jöckel KH,
et al: Dose-escalated radiotherapy with PET/CT based treatment
planning in combination with induction and concurrent chemotherapy
in locally advanced (uT3/T4) squamous cell cancer of the esophagus:
mature results of a phase I/II trial. Radiat Oncol.
16(59)2021.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Wang R, Liu S, Chen B, Li Q, Cheng X, Zhu
Y, Zhang L, Hu Y, Liu M, Hu Y and Xi M: Prognostic significance of
PET/CT and its association with immuno-genomic profiling in
oesophageal squamous cell carcinoma treated with immunotherapy plus
chemoradiotherapy: results from a phase II study. Br J Cancer.
131:709–717. 2024.PubMed/NCBI View Article : Google Scholar
|
